Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Semnur Pharmaceuticals, Inc./ EFFECT

Notice of Effectiveness · EFFECT

Semnur Pharmaceuticals, Inc.

SMNROTCEQUITYCurrent

Notice of Effectiveness

Filed May 18, 2026Accepted May 19, 2026, 12:15 AM EDTCIK 1913577Accession 9999999995-26-001684
View company →Permanent SEC source ↗
Share

Company context

Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. Semnur is headquartered in Palo Alto, California.

Current securities

SMNROTC · EQUITY · CurrentSMNRWOTC · WARRANT · Current
Historical securities (6)
DECAUNASDAQ · UNIT · Historical · closed Mar 17, 2025DNQAFOTC · EQUITY · Historical · closed Sep 23, 2025DNQAFOTC · EQUITY · Historical · closed Sep 23, 2025DNQUFOTC · UNIT · Historical · closed Sep 22, 2025DNQWFOTC · WARRANT · Historical · closed Sep 23, 2025DNQWFOTC · WARRANT · Historical · closed Sep 23, 2025

Recent company filings

  1. 10-Q filingNov 4, 2026
  2. 10-Q filingAug 10, 2026
  3. 424B3 filingJul 7, 2026
  4. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureJul 7, 2026
  5. 424B3 filingJul 1, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.